Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system

References

• Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002; 27:552-8; PMID:12417130; http://dx.doi.org/10.1016/S0968-0004(02)02177-1
   PubMed Web of Science ®Google Scholar
• Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep 2007; 1:122-34; PMID:18388640; http://dx.doi.org/10.1097/DMP.0b013e318158c5fd
   PubMed Web of Science ®Google Scholar
• Karalewitz AP, Barbieri JT. Vaccines against botulism. Curr Opin Microbiol 2012; 15:317-24; PMID:22694934; http://dx.doi.org/10.1016/j.mib.2012.05.009
   PubMed Web of Science ®Google Scholar
• Middlebrook JL. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev 2005; 57:1415-23; PMID:15896873; http://dx.doi.org/10.1016/j.addr.2005.01.016
   PubMed Web of Science ®Google Scholar
• Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 2007; 27:303-18; PMID:18197811; http://dx.doi.org/10.1615/CritRevImmunol.v27.i4.20
   PubMed Web of Science ®Google Scholar
• Smith LA. Botulism and vaccines for its prevention. Vaccine 2009; 27(Suppl 4):D33-9; PMID:19837283; http://dx.doi.org/10.1016/j.vaccine.2009.08.059
   PubMed Web of Science ®Google Scholar
• Webb RP, Smith LA. What next for botulism vaccine development? Expert Rev Vaccines 2013; 12:481-92; PMID:23659297; http://dx.doi.org/10.1586/erv.13.37
   PubMed Web of Science ®Google Scholar
• Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30:E9; PMID:11788735; http://dx.doi.org/10.1093/nar/30.2.e9
   PubMed Web of Science ®Google Scholar
• Yu R, Wang S, Yu YZ, Du WS, Yang F, Yu WY, Sun ZW. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library. J Biomol Screen 2009; 14:991-8; PMID:19726786; http://dx.doi.org/10.1177/1087057109343206
   PubMed Web of Science ®Google Scholar
• Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog 1998; 25:91-9; PMID:9712688; http://dx.doi.org/10.1006/mpat.1998.0214
   PubMed Web of Science ®Google Scholar
• Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, Sandhoff K, Proia RL, Acharya KR, Bigalke H, et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A 2007; 104:359-64; PMID:17185412; http://dx.doi.org/10.1073/pnas.0609713104
   PubMed Web of Science ®Google Scholar
• Jin R, Rummel A, Binz T, Brunger AT. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006; 444:1092-5; PMID:17167421; http://dx.doi.org/10.1038/nature05387
   PubMed Web of Science ®Google Scholar
• Yu YZ, Wang WB, Li N, Wang S, Yu WY, Sun ZW. Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate. Biologicals 2010; 38:658-63; PMID:20805035; http://dx.doi.org/10.1016/j.biologicals.2010.08.001
   PubMed Web of Science ®Google Scholar
• Zarebski LM, Vaughan K, Sidney J, Peters B, Grey H, Janda KD, Casadevall A, Sette A. Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines 2008; 7:55-74; PMID:18251694; http://dx.doi.org/10.1586/14760584.7.1.55
   PubMed Web of Science ®Google Scholar
• Aoki KR, Smith LA, Atassi MZ. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 2010; 30:167-87; PMID:20370628; http://dx.doi.org/10.1615/CritRevImmunol.v30.i2.50
   PubMed Web of Science ®Google Scholar
• Shearer JD, Vassar ML, Swiderski W, Metcalfe K, Niemuth N, Henderson I. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B). Vaccine 2010; 28:7313-8; PMID:20816903; http://dx.doi.org/10.1016/j.vaccine.2010.08.076
   PubMedGoogle Scholar
• Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995; 63:2738-42; PMID:7790092
   PubMed Web of Science ®Google Scholar
• Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, Simpson LL. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007; 75:3043-54; PMID:17371853; http://dx.doi.org/10.1128/IAI.01893-06
   PubMed Web of Science ®Google Scholar
• Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008; 76:1314-8; PMID:18070903; http://dx.doi.org/10.1128/IAI.01025-07
   PubMed Web of Science ®Google Scholar
• Yu YZ, Li N, Zhu HQ, Wang RL, Du Y, Wang S, Yu WY, Sun ZW. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009; 27:2816-22; PMID:19428892; http://dx.doi.org/10.1016/j.vaccine.2009.02.091
   PubMed Web of Science ®Google Scholar
• Yu YZ, Zhang SM, Ma Y, Zhu HQ, Wang WB, Du Y, Zhou XW, Wang RL, Wang S, Yu WY, et al. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Clin Immunol 2010; 137:271-80; PMID:20696619; http://dx.doi.org/10.1016/j.clim.2010.07.005
   PubMed Web of Science ®Google Scholar
• Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998; 66:4817-22; PMID:9746584
   PubMed Web of Science ®Google Scholar
• Potter KJ, Bevins MA, Vassilieva EV, Chiruvolu VR, Smith T, Smith LA, Meagher MM. Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr Purif 1998; 13:357-65; PMID:9693060; http://dx.doi.org/10.1006/prep.1998.0910
   PubMed Web of Science ®Google Scholar
• Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000; 82:955-66; PMID:11086225; http://dx.doi.org/10.1016/S0300-9084(00)01173-1
   PubMed Web of Science ®Google Scholar
• Gurkan C, Ellar DJ. Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb Cell Fact 2005; 4:33; PMID:16336647; http://dx.doi.org/10.1186/1475-2859-4-33
   PubMedGoogle Scholar
• Villaflores OB, Hsei CM, Teng CY, Chen YJ, Wey JJ, Tsui PY, Shyu RH, Tung KL, Yeh JM, Chiao DJ, et al. Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system. J Virol Methods 2013; 189:58-64; PMID:23313783; http://dx.doi.org/10.1016/j.jviromet.2012.11.035
   PubMed Web of Science ®Google Scholar
• Zhou Y, Singh BR. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif 2004; 34:8-16; PMID:14766296; http://dx.doi.org/10.1016/j.pep.2003.10.015
   PubMedGoogle Scholar
• Rummel A, Mahrhold S, Bigalke H, Binz T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 2004; 51:631-43; PMID:14731268; http://dx.doi.org/10.1046/j.1365-2958.2003.03872.x
   PubMed Web of Science ®Google Scholar
• Singh BR. Intimate details of the most poisonous poison. Nat Struct Biol 2000; 7:617-9; PMID:10932240; http://dx.doi.org/10.1038/77900
   PubMedGoogle Scholar
• Atassi MZ, Taruishi M, Naqvi M, Steward LE, Aoki KR. Synaptotagmin II and gangliosides bind independently with botulinum neurotoxin B but each restrains the other. Protein J 2014; 33:278-88; PMID:24740609; http://dx.doi.org/10.1007/s10930-014-9557-y
   PubMedGoogle Scholar
• Gao YL, Gao S, Kang L, Nie C, Wang JL. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen. Hum Vaccin 2010; 6:462-6; PMID:20519939; http://dx.doi.org/10.4161/hv.6.6.11709
   PubMed Web of Science ®Google Scholar
• Smith LA. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 1998; 36:1539-48; PMID:9792170; http://dx.doi.org/10.1016/S0041-0101(98)00146-9
   PubMed Web of Science ®Google Scholar
• Yu Y, Yu J, Li N, Wang S, Yu W, Sun Z. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors. Vaccine 2009; 27:6148-53; PMID:19712769; http://dx.doi.org/10.1016/j.vaccine.2009.08.022
   PubMed Web of Science ®Google Scholar
• Yu YZ, Guo JP, An HJ, Zhang SM, Wang S, Yu WY, Sun ZW. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors. Vaccine 2013; 31:2427-32; PMID:23583890; http://dx.doi.org/10.1016/j.vaccine.2013.03.046
   PubMed Web of Science ®Google Scholar
• Yu YZ, Ma Y, Chen YX, Gong ZW, Wang S, Yu WY, Sun ZW. Binding activity and immunogenic characterization of recombinant C-terminal quarter and half of the heavy chain of botulinum neurotoxin serotype A. Hum Vaccin 2011; 7:1090-5; PMID:21941093; http://dx.doi.org/10.4161/hv.7.10.16763
   PubMed Web of Science ®Google Scholar